--- title: "Biofrontera | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 12 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295803464.md" datetime: "2026-08-13T13:03:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295803464.md) - [en](https://longbridge.com/en/news/295803464.md) - [zh-HK](https://longbridge.com/zh-HK/news/295803464.md) generator: "portal-rs" --- # Biofrontera | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 12 M Revenue: As of FY2026 Q2, the actual value is USD 12 M, beating the estimate of USD 9.5 M. EPS: As of FY2026 Q2, the actual value is USD -0.05, beating the estimate of USD -0.105. EBIT: As of FY2026 Q2, the actual value is USD -455 K. ### Second Quarter 2026 Financial Highlights #### Net Product Revenue Biofrontera Inc. reported net product revenue of $12.0 million, marking a 32.9% increase from $9.0 million in the prior-year period. #### Gross Margin The company achieved a gross margin of 80%, an improvement of approximately 920 basis points compared to 71% in the prior-year period. #### Net Loss Net loss was - $0.6 million, a significant reduction from - $5.3 million in the prior-year period. #### Adjusted EBITDA Adjusted EBITDA improved to - $0.2 million, compared to - $5.1 million in the prior-year period, representing an improvement of approximately $5.0 million. #### Cost of Revenues Cost of revenues was $2.4 million, down from $2.6 million in the prior-year period. #### Gross Profit Gross profit stood at $9.6 million, up from $6.4 million in the second quarter of 2025. #### Selling, General and Administrative Expenses These expenses decreased by $0.9 million to $9.7 million from $10.6 million in the prior-year quarter. #### Research and Development Expenses Research and development expenses were $0.4 million, compared to $0.9 million in the prior-year quarter. #### Loss from Operations Loss from operations was - $0.524 million, a notable improvement from - $5.079 million in the prior-year period. ### First Half 2026 Financial Highlights #### Net Product Revenue Net product revenue for the first six months was $22.1 million, an increase of 25.4% from $17.6 million in the prior-year period. #### Gross Margin Gross margin was 80%, up from 67% in the prior-year period. #### Net Loss Net loss was - $5.4 million, an improvement from - $9.5 million in the prior-year period. #### Adjusted EBITDA Adjusted EBITDA was - $3.7 million, compared to - $9.5 million in the prior-year period. #### Cash Used in Operating Activities Cash used in operating activities was $1.7 million, a 76% reduction from $7.2 million in the prior-year period. #### Cost of Revenues Cost of revenues was $4.5 million, compared to $5.9 million in the prior-year period. #### Gross Profit Gross profit was $17.6 million, compared to $11.7 million in the prior-year period. #### Selling, General and Administrative Expenses These expenses increased to $20.7 million from $19.3 million in the prior-year period. #### Research and Development Expenses Research and development expenses were $1.3 million, compared to $2.1 million in the prior-year period. #### Loss from Operations Loss from operations was - $4.844 million, an improvement from - $9.629 million in the prior-year period. ### Balance Sheet and Cash Flow (as of June 30, 2026) #### Cash and Cash Equivalents Cash and cash equivalents stood at $4.7 million, down from $6.4 million as of December 31, 2025. #### Total Liabilities Total liabilities remained essentially unchanged at $18.1 million compared to December 31, 2025. #### Outstanding Indebtedness The company’s outstanding indebtedness consisted of $4.6 million in convertible notes, net, maturing in November 2027. #### Total Stockholders’ Equity Total stockholders’ equity was $6.0 million, compared to $10.5 million at December 31, 2025. ### Outlook / Guidance Biofrontera Inc. anticipates continued strong underlying demand for Ameluz® and expects to launch Ameluz® for superficial basal cell carcinoma (sBCC) in Q1 2027. The company is progressing towards achieving cash flow breakeven in 2026. This goal is expected to be unaffected by the ITC order impacting RhodoLED XL lamps. ### Related Stocks - [BFRI.US](https://longbridge.com/en/quote/BFRI.US.md) ## Related News & Research - [BFRI: Record revenue growth and margin gains in Q2 2026, with losses and cash use sharply reduced](https://longbridge.com/en/news/295805792.md) - [Biofrontera (BFRI) Q2 2026 Earnings Call: Revenue Up 33%, Gross Margin Reaches 80%](https://longbridge.com/en/news/295900599.md) - [Northann amends 8-K to file former auditor LAO Professionals’ letter on resignation](https://longbridge.com/en/news/296825824.md) - [Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split](https://longbridge.com/en/news/296471274.md) - [Acres Commercial Realty files amended 8-K with pro forma financials for ACC internalization merger](https://longbridge.com/en/news/296825345.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**